

## PHASE II DOG MONEPANTEL CANCER TRIAL UPDATE

- Some canine cancer patients have completed the full 28 day course of treatment.
- Recruitment is continuing for additional eligible patients
- Covid-19 pandemic reduces capacity of some veterinarians to participate in clinical trials
- WAVES Perth and the Animal Referral Hospital (ARH) Brisbane continue enrolments
- U-Vet Werribee, ARH Homebush and University Veterinary Teaching Hospital Sydney (UVTHS) temporarily cease enrolling new cases, however, dogs currently enrolled continue on the trial
- Trial overseen by Dr Claire Cannon, U-Vet Werribee Animal Hospital

**31 March 2020 – Perth, Australia:** PharmAust Ltd (ASX:PAA), a clinical-stage oncology company is pleased to provide an update on recruitment for its veterinary Phase II trial investigating the effects of monepantel upon dogs with treatment naïve B cell lymphoma.

A number of canine patients with cancer are currently being treated at different centres and some have completed the full 28 day course of treatment.

While recruitment to date has been going to plan, due to the COVID-19 situation and related shutdown measures at State and federal government levels, recruitment at some clinics is on hold.

While enrolments at WAVES in Perth and the ARH in Brisbane continue, new enrolments at U-Vet Werribee, ARH Homebush and UVTHS will temporarily cease until further notice. We are pleased that dogs currently enrolled at these latter sites will continue on the trial until their 28 day trial periods are completed.

The trial continues to be overseen by Dr Claire Cannon, Head of Small Animal Medicine and Oncology at the University of Melbourne's U-Vet Werribee Animal Hospital. Existing dogs on the trial have sufficient tablets to continue treatment and dogs who have completed treatment and are on the long-term maintenance dose also have access to MPL tablets. While some sites may be disrupted, PharmAust confirms that the trial is ongoing and recruitment is continuing including a new dog commencing treatment last week.

PharmAust's Chief Scientific Officer Dr Richard Mollard stated, "PharmAust is thankful to the participating veterinarians, their staff and the dog owners who are treating pet dogs with naïve B cell lymphoma. The dogs have received excellent care during this Phase II clinical trial."

"Following consultation with the trial manager Dr Claire Cannon, PharmAust considers it in the best interests of dogs and their owners to reduce the consultation visits and intensity required for the trial in some circumstances. This means a pause on recruitment at some centres due to COVID-19. We do hope to reopen enrolment at all trial centres as soon as possible. PharmAust looks forward to again working with all veterinarians, their staff, pet owners and their dogs in the near future to provide the best possible care for dogs and finish the trial."

This announcement is authorised by the Board

**Enquiries:**

**Dr Roger Aston**  
**Executive Chairman and CEO**  
**Tel: 0402 762 204**  
[rogeraston@pharmaust.com](mailto:rogeraston@pharmaust.com)

**Dr Richard Mollard**  
**Chief Scientific Officer**  
**Tel: 0418 367 855**  
[rmollard@pharmaust.com](mailto:rmollard@pharmaust.com)

**About PharmAust (PAA):**

PAA is a clinical-stage company developing targeted cancer therapeutics for humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs; was well tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug in Phase 2 clinical trials.

**About U-Vet:**

The University of Melbourne's U-Vet Werribee Animal Hospital is one of Australia's leading veterinary hospital facilities, based in Werribee. U-Vet offers complete animal care to the public including general practice (primary and preventative care, exotic pet care), a suite of specialist referral services, specialist support services, 24-hour emergency care and specialist referral equine services. The hospital also trains the next generation of veterinarians and veterinary specialists with the assistance of its academic staff, who are world leaders in clinical excellence and research.

**About University of Melbourne:**

Established in 1853, the University of Melbourne is a public-spirited institution that makes distinctive contributions to society in research, learning and teaching and engagement. It's consistently ranked among the leading universities in the world, with international rankings of world universities placing it as number 1 in Australia and number 32 in the world (Times Higher Education World University Rankings 2017-2018). The University's distinctive Melbourne experience helps graduates become well-rounded, thoughtful and skilled professionals – making a positive impact across the globe. Its research helps solve social, economic and environmental challenges the world is facing today and into the future.